Overview
GOSS market data
Price History
GOSS price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.75 Diluted earnings per share over the trailing twelve months.
- Beta
- 2.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -324.8% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.11 – $3.87 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $87.2M · P/B 6.95 · P/S 1.57.
Company News
Piper Sandler Maintains Overweight on Gossamer Bio, Lowers Price Target to $4Benzinga · Aug 14, 2026, 4:35 PM
Gossamer Bio Q2 EPS $(0.08) Beats $(0.12) Estimate, Sales $9.238M Beat $5.193M EstimateBenzinga · Aug 13, 2026, 8:18 PM
This Crowdstrike Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For TuesdayBenzinga · Jul 28, 2026, 1:02 PM
This Honeywell Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For TuesdayBenzinga · Jul 28, 2026, 11:33 AM
Leerink Partners Upgrades Gossamer Bio to Outperform, Maintains Price Target to $1Benzinga · Jul 28, 2026, 10:50 AM
Why Celestica Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving PremarketBenzinga · Jul 28, 2026, 9:01 AM
8-K filing — Gossamer Bio, Inc. (GOSS)SEC EDGAR · Jul 27, 2026, 8:01 PM
Gossamer Bio shares are trading higher after a pre‑NDA meeting and FDA minutes outlined a path to a September 2026 NDA filing for seralutinib in PAH. The company also regained global rights to the drug and won shareholder approval for a note exchange and reverse split to bolster its capital structure.Benzinga · Jul 27, 2026, 6:16 PM
Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug CandidateBenzinga · Jul 27, 2026, 6:11 PM
HC Wainwright & Co. Reiterates Buy on Gossamer Bio, Maintains $2 Price TargetBenzinga · Jul 27, 2026, 4:51 PM